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Abstract
In pediatric patients, basal testosterone and gonadotropin levels may be uninformative in the assessment of
testicular function. Measurement of serum anti-Müllerian hormone (AMH) has become increasingly widespread
since it provides information about the activity of the male gonad without the need for dynamic tests, and also
reflects the action of FSH and androgens within the testis. AMH is secreted in high amounts by Sertoli cells from
fetal life until the onset of puberty. Basal AMH expression is not dependent on gonadotropins or sex steroids;
however, FSH further increases and testosterone inhibits AMH production. During puberty, testosterone induces
Sertoli cell maturation, and prevails over FSH on AMH regulation. Therefore, AMH production decreases. Serum
AMH is undetectable in patients with congenital or acquired anorchidism, or with complete gonadal dysgenesis.
Low circulating levels of AMH may reflect primary testicular dysfunction, e.g. in certain patients with
cryptorchidism, monorchidism, partial gonadal dysgenesis, or central hypogonadism. AMH is low in boys with
precocious puberty, but it increases to prepubertal levels after successful treatment. Conversely, serum AMH
remains at high, prepubertal levels in boys with constitutional delay of puberty. Serum AMH measurements are
useful, together with testosterone determination, in the diagnosis of patients with ambiguous genitalia: both are
low in patients with gonadal dysgenesis, including ovotesticular disorders of sex development, testosterone is
low but AMH is in the normal male range or higher in patients with disorders of androgen synthesis, and both
hormones are normal or high in patients with androgen insensitivity. Finally, elevation of serum AMH above
normal male prepubertal levels may be indicative of rare cases of sex-cord stromal tumors or Sertoli cell-limited
disturbance in the McCune Albright syndrome.
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Background
In the adult male, the appraisal of the endocrine func-
tion of the gonadal axis usually relies on the assessment
of serum levels of gonadotropins, testosterone and in-
hibin B. In pediatric ages, basal testosterone and go-
nadotropin levels may be largely uninformative. In fact,
gonadotropin and testosterone secretion is active only
during 3 to 6 months after birth in the male; thereafter,
their serum levels remain very low or undetectable until
the onset of puberty [1]. However, the use of non-
classical biomarkers, like anti-Müllerian hormone
(AMH), has become increasingly widespread since it not
only informs about the activity of the male gonad with-
out the need for dynamic tests but also reflects the ac-
tion of FSH and androgens within the gonad [2]. This
review will address the usefulness of AMH as a bio-
marker of testicular function in prepubertal and adoles-
cent males, based on the knowledge of the endocrine
regulation of testicular AMH secretion during pre- and
post-natal development.
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Developmental physiology of the hypothalamic-
pituitary-testicular axis
Testicular function is mainly regulated by the pituitary
gonadotropins LH and FSH, which in turn depend on
gonadotropin-releasing hormone (GnRH) action, from
the hypothalamus. This hypothalamic-pituitary-gonadal
axis evolves throughout development, from fetal life
through adulthood. Specific maturational changes take
place both in these organs as a whole and in the differ-
ent cell types that make them up.
While sperm production has classically been the focus
of adult reproductive function, somatic cells are crucial
for the maintenance of spermatogenesis and gamete pro-
duction. In the interstitial tissue, Leydig cells synthesize
androgens and the insulin-like factor 3 (INSL3) [3],
whereas in the seminiferous tubules, Sertoli cells regu-
late the nutrients and factors that reach the germ cells
by means of the blood-testis barrier. Sertoli cells not
only regulate the inflow of external substances, but also
produce several substances which are critical to the
proper progression of spermatogenesis [4]. Therefore, it
appears evident that the assessment of gonadal function
and the definition of male hypogonadism should rely on
the understanding of normal testicular physiology result-
ing from the integrated function of the tubular and inter-
stitial compartments, and its developmental changes from
fetal life through maturity [5].
Sertoli cells as the most active population in the
developing testis
Unlike the adult testis, where germ cells represent most
of the gonadal size and Leydig cells are the most active
endocrine cell population, in the prepubertal testis, Ser-
toli cells are the most numerous [6] and active testicular
cell population [7, 8]. Even though Sertoli cells remain
active during infancy and childhood, the testes have
been erroneously considered as quiescent due to the re-
duced activity of the hypothalamic-gonadotrope axis.
This activity is clearly reflected on the high levels of
serum AMH and inhibin B.
Earlier in development, during fetal life and early in-
fancy, the active hypothalamic-gonadotrope axis has ef-
fects on the seminiferous cords, reflected in the
proliferation of both immature germ and Sertoli cells
[9]. Sertoli cell proliferation, essentially dependent on
FSH, results in a moderate increase in testicular volume,
which cannot be detected by palpation [6, 10–12] but is
clearly measurable by ultrasonography [13] (Fig. 1a).
It is around the onset of puberty that Sertoli cells
undergo major morphological and physiological changes,
leading to the switch from a proliferative, immature state,
to a quiescent, mature one. Morphologically, there are
changes in the nucleus and nucleolus [14]. The blood-
testis barrier becomes distinct, creating two separate
compartments within the tubules. Germ cells in the
adluminal compartment become dependent on the func-
tion of the, now mature, Sertoli cells [15]. These matur-
ational changes observed in Sertoli cells are induced
essentially by an increase of intratesticular testosterone
concentration early in pubertal development [14, 16].
Interestingly, Sertoli cells do not show maturational
changes, in spite of the active androgen testicular produc-
tion, during fetal and neonatal periods of life. This is due
to the fact that before the age of 1 yr in humans [17, 18],
the androgen receptor is not expressed in Sertoli cells
(Fig. 1b), as experimentally confirmed in mice [19, 20].
AMH as a marker of prepubertal Sertoli cells:
physiological concepts
AMH, also known as Müllerian Inhibiting Substance
(MIS), is a glycoprotein dimer belonging to the trans-
forming growth factor β (TGF-β) family [21, 22], which
plays a major role in fetal sex differentiation by inducing
the regression of the Müllerian ducts.
In the male, AMH expression begins when the semin-
iferous cords differentiate in the fetus [23], and remains
high until puberty [23–26] (Fig. 1b and Table 1). The on-
set of AMH expression in fetal life is independent from
gonadotropins, and involves several transcription factors.
Initially, SOX9 binds to the AMH promoter [27, 28] and
triggers its expression; subsequently, other transcription
factors, such as SF1 [27, 29, 30], GATA4 [30, 31] and
WT1 [32], further increase AMH production.
Because AMH is exclusively secreted into the circula-
tion by Sertoli cells [33, 34], it has become one of the
most useful markers to study testicular function during
the prepubertal period in the male [35–37]. In the fe-
male, AMH is produced by ovarian granulosa cells of
primary and small growing follicles up until transition to
menopause [38–41].
AMH as a marker of FSH action in the testis
Once AMH expression is triggered independently of go-
nadotropins in fetal and postnatal life, FSH further in-
creases testicular AMH output by inducing Sertoli cell
proliferation and up-regulating AMH transcription
(Fig. 2), which explains why patients with congenital
central (hypogonadotropic) hypogonadism have low
AMH serum levels that increase after treatment with ex-
ogenous FSH [42, 43]. These results clearly demonstrate
that serum AMH is an adequate marker of FSH action
in the prepubertal testis. The usefulness of serum AMH
levels as an indicator of FSH action has also been stud-
ied in rodents: the absence of FSH stimulation during
fetal and neonatal life results in low levels of AMH due
to a decrease in Sertoli cell number and AMH expres-
sion, correlating also with smaller testes [44]. FSH ad-
ministration to neonatal mice provokes an increase in
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testicular volume and in AMH transcription through the
classical FSH receptor transduction pathway involving
Gsα protein, adenylyl cyclase and stimulation of protein
kinase A (PKA) activity, leading to the involvement of
the aforementioned transcription factors SOX9, SF1,
GATA4, and also of NFκB and AP2 [2, 20, 44, 45]
(Fig. 2).
AMH as a marker of androgen action in the testis
At the onset of puberty, AMH serum levels start declin-
ing, as compared to prepubertal levels, and continue to
decrease throughout puberty [46] (Fig. 1b and Table 1),
as a consequence of the negative effect exerted by intra-
testicular testosterone via the androgen receptor [20, 47]
(Fig. 3). The androgen-mediated downregulation of
AMH expression occurs concomitantly with the appear-
ance of meiotic germ cells in the seminiferous tubules,
indicating Sertoli cell maturation [20, 47, 48]. The in-
hibitory effect of androgens on AMH expression over-
rides the FSH-dependent stimulation in normal puberty
(Fig. 3). The androgen-dependent inhibition of AMH
a
b
Fig. 1 Developmental physiology of the testis in postnatal life. a: Testicular volume increases slightly during infancy and childhood (from birth to
the age of 8–10 yr), as measured by ultrasonography, mainly due to the increase of the Sertoli cell population. After pubertal onset, clinically
defined by a testicular volume of 4 ml as measured by comparison with the orchidometer, testicular volume increases drastically due to the onset of
pubertal spermatogenesis, which requires androgen-dependent Sertoli cell maturation. b: Schematic serum levels of gonadotropins (FSH and LH),
testosterone (T), inhibin B (Inh B) and AMH from birth through adulthood (left axis) and percentage of Sertoli cells expressing the androgen receptor
(AR, right axis). Reprinted, with permission, from Rey et al. [85], copyright 2009 Wiley-Liss, Inc.
Table 1 Serum AMH levels in normal boys
Age Serum AMH
pmol/la ng/mla
<14 days 250–1000 35–140
15 days – 6 months 400–1500 55–210
6 months – 2 years 600–2300 85–320
2–9 years 400–1800 55–250
9–18 years:
Tanner 1 250–1400 35–200
Tanner 2 70–1000 10–140
Tanner 3 30–400 4–55
Tanner 4 30–160 4–22
Tanner 5 30–150 4–21
Adults 25–130 3–18
aReference levels are taken from refs. [24, 25, 26]. For calculations, 1 ng/ml is
equivalent to 7.14 pmol/l
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has also been observed in central precocious puberty
and in male-limited gonadotropin-independent preco-
cious puberty (testotoxicosis), clearly indicating that an-
drogens are responsible for AMH down-regulation
independently of gonadotropin levels [46]. Interestingly,
the decline of AMH levels reflects an increase in intra-
testicular, and not necessarily circulating, testosterone
concentration, as observed in the earliest stages of pu-
berty [26, 46]. Conversely, in patients with central hypo-
gonadism treated with exogenous testosterone, serum
AMH remains high indicating that intratesticular andro-
gen concentration is low [49]. This is in line with the
lack of increase in testicular volume, since pubertal and
adult spermatogenesis needs sufficient intratesticular an-
drogen concentration to develop. Similarly, in cases of
constitutional delay of puberty [50, 51] or of defective
androgen production or sensitivity [20, 52, 53], the lack
of androgen production or action results in the mainten-
ance of high AMH levels (Fig. 3).
Androgen-mediated AMH down-regulation is also not
observed in fetal life and during the first year of postna-
tal life (Fig. 3), even in patients with precocious puberty,
owing to the above-mentioned physiological androgen
insensitivity of Sertoli cells, which is consequence of the
lack of androgen receptor expression in Sertoli cells in
those periods of life [17, 18, 54, 55].
Ever since Alfred Jost postulated the existence of
AMH [56], it has been referred to as the fetal testicular
hormone guiding the regression of the Müllerian ducts
in the male fetus. The biological reasons for ongoing ex-
pression of AMH throughout childhood have been the
source of many debates. Nonetheless, AMH detection in
serum has become a very powerful tool in pediatrics. In
the following part of this review, we aim to summarize
the main conditions in which AMH can be used as a
proper marker of Sertoli cell function in boys.
Serum AMH in the diagnosis of conditions
affecting testicular function
Cryptorchidism
Cryptorchidism is a clinical sign with many different etiolo-
gies [57, 58]. It may be a consequence of primary (usually
called hypergonadotropic) or central (hypogonadotropic)
hypogonadism, or even result from anatomical defects of
the inguinal region or the abdominal wall (i.e. not due to
hypogonadism). Cryptorchidism may be associated with
normal or impaired Sertoli cell function [59, 60] (Table 2).
In boys with bilateral cryptorchidism, AMH is low in ap-
proximately 75 % of those with non-palpable gonads and
35 % of those with inguinal gonads, indicating Sertoli cell
dysfunction [61].
Non-palpable gonads
In patients with non-palpable gonads, it is necessary to
determine whether there is intraabdominal functional
testicular tissue. The utility of gonadotropins, as indirect
markers, is limited since they may be normal even in
anorchid children [1]. Conversely, in boys with non-
palpable gonads detectable serum AMH levels are highly
predictive of the existence of testicular tissue while an
undetectable AMH value is indicative of anorchidism
[33, 34] (Table 2). An extremely rare exception is the
Persistent Müllerian Duct Syndrome caused by AMH
gene mutations, which may explain the finding of un-
detectable serum AMH in a boy with abdominal testes
[62]. Vanishing or regression of testicular tissue occur-
ring in the second half of fetal life does not preclude
virilization, but micropenis and hypoplastic scrotum
occur (Table 2). Serum AMH is low or undetectable, ac-
cording to the amount of remaining functional testicular
tissue [33, 34].
Monorchidism
Monorchidism is the presence of a solitary testis, which
may undergo a compensatory volume increase. There is
a dissociated capacity of the remaining testis to compen-
















Fig. 2 AMH as a marker of FSH action in the prepubertal testis. FSH
provokes Sertoli cell proliferation and increases AMH transcription in
each Sertoli cell through the classical FSH receptor (FSH-R)
transduction pathway involving Gsα protein, adenylyl cyclase (AC)
and stimulation of protein kinase A (PKA) activity, leading to an
increased AMH promoter activity induced by transcription factors
SOX9, SF1, GATA4, NFκB and AP2
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function is largely compensated, lower AMH and higher
FSH in monorchid boys indicate that Sertoli cell prolifer-
ation and function is insufficient to fully compensate the
function of the absent one [63].
Klinefelter syndrome
No overt signs of hypogonadism are evident before pu-
berty in Klinefelter syndrome, a sex-chromosome aneu-
ploidy with late-onset testicular dysgenesis. Serum AMH
is normal during childhood and early puberty, in correl-
ation with normal inhibin B and FSH, indicating that Ser-
toli cell function is preserved until advanced stages of
puberty [64, 65]. At the onset of puberty, like in normal
boys, androgens provoke a physiological decrease in
serum AMH also in patients with Klinefelter syndrome.
However, in the latter, Sertoli cell function deteriorates
progressively from mid-puberty, resulting in extremely
low or undetectable AMH, in coincidence with undetect-
able inhibin B, very high FSH levels and small testis vol-
ume. Germ cell degeneration has been described already
in early fetal development with a clear progression during
postnatal life, mainly after pubertal onset [66].
Cryptorchidism and micropenis: suspicion of central
hypogonadism
During the neonatal period and infancy, some clinical
features associated with cryptorchidism, like micropenis
and microorchidism, or the coexistence of anosmia or
other pituitary hormone deficiencies are suggestive of
central hypogonadism. Serum AMH is below the normal
range in most cases of isolated central hypogonadism
and of multiple pituitary hormone deficiency [42, 43, 49]
(Table 2 and Fig. 3), although normal AMH levels do
not rule out the diagnosis [67]. The lack of FSH stimula-
tion during fetal and neonatal life is responsible for the
decreased Sertoli cell numbers and low AMH expression
in patients with congenital hypogonadotropic hypo-
gonadism.[44, 45] The increase in serum AMH in those
patients receiving FSH may be useful to monitor treat-
ment efficacy [42, 43, 49].
Fig. 3 Regulation of testicular AMH production by FSH and testosterone in normal and pathological conditions. Basal AMH production is independent
of gonadotropins or androgens; however, FSH stimulates and testosterone inhibits AMH expression. In the fetal period and during the first months
of postnatal life (I), the hypothalamic-gonadotrope is active: FSH stimulates AMH production, whereas testosterone cannot inhibit it because Sertoli
cells do not yet express the androgen receptor. During childhood, and in boys >14 years-old with constitutional delay of puberty (II), the
hypothalamic-gonadotrope is “quiescent”, resulting in little or no effect on basal AMH production. In boys with normal or precocious puberty (III) with
high intratesticular androgen concentrations (central precocious puberty, testotoxicosis, Leydig cell tumors), testosterone inhibition overrides FSH
stimulation, resulting in a decrease in serum AMH. In patients with central hypogonadism (IV), only basal AMH production is observed, with no further
stimulation or inhibition. In patients with disorders of sex development due to androgen synthesis defects (V) or androgen insensitivity (VI), the
positive effect of FSH cannot be antagonized by testosterone, resulting in high AMH production in infancy and pubertal age. AR: androgen receptor;
CAIS: complete androgen insensitivity syndrome; CDP: constitutional delay of puberty; FSH-R: FSH receptor; LH-R: LH receptor; T: testosterone
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Pubertal delay
Sertoli cells markers have been assessed to distinguish
between constitutional delay of puberty and central
hypogonadism. AMH is within normal prepubertal levels
in boys with constitutional delay of puberty, reflecting a
eugonadal state in these patients [51]. In untreated pa-
tients of pubertal age with congenital central hypo-
gonadism, serum AMH levels are above those expected
for age –reflecting that intratesticular testosterone is too
low to inhibit AMH– but below those expected for Tan-
ner stage 1, indicating that Sertoli cells have not been
exposed to FSH [49, 68] (Table 2 and Fig. 3). Treatment
with recombinant FSH provokes an increase in serum
AMH, whereas further administration of hCG results in
an elevation of intratesticular androgen levels and a de-
cline in AMH [42, 49]. Conversely, down-regulation of
AMH is less notorious when patients receive exogenous
testosterone, probably due to the lower intratesticular
androgen levels obtained with this treatment [49].
Precocious puberty
Like in normal puberty, serum AMH declines in boys
with central or gonadotropin-independent precocious
puberty, showing the well-known inhibition exerted by
androgens on Sertoli cell AMH production (Table 2 and
Figs. 3 and 4). Low AMH together with increased testos-
terone levels for chronological age are suggestive of pre-
cocious testicular maturation.
Serum AMH determination may be particularly help-
ful in the diagnostic workup of boys with incipient signs
of precocious puberty, e.g. testis volume increase from 2
to 3 ml with or without penile enlargement, in whom
basal gonadotropin and testosterone levels are not yet
informative. As already mentioned, the decline in serum
AMH is an early biochemical sign of the increase in
intratesticular testosterone concentration [69]. In infants
below the age of 1 yr, AMH may not be useful (Figs. 3
and 4): serum levels are normal, owing to the lack of an-
drogen receptor expression in Sertoli cells at that age,
which makes this particular cell population of the testis
transiently insensitive to androgens [18].
AMH may also be useful to monitor effectiveness during
treatment with GnRH analogues, ketoconazole or anti-
androgens. The decrease in testosterone production or ac-
tion is reflected in the recovery of prepubertal AMH levels
[18, 46]. Interestingly, lack of adherence to treatment
resulting in intermittent inhibition of testosterone produc-
tion can be suspected when AMH does not normalize [46].
Table 2 Serum AMH levels according to clinical presentation
Serum AMH










PMDS - AMHR mutation
--
Micropenis Fetal testicular regression Primary hypogonadism
Central hypogonadism
Malformative micropenis --





















DSD 46,XY Complete gonadal
dysgenesis












Serum AMH levels are considered low, normal or high as compared to those expected for age in normal boys
AMH-R AMH receptor, DSD disorders of sex development, PMDS persistent Müllerian duct syndrome
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Prepubertal macro-orchidism
Although precocious puberty is one of the classic com-
ponents of McCune-Albright syndrome, macro-
orchidism in the absence of androgen-dependent sec-
ondary sexual characteristics has also been reported in
boys [70, 71]. In some cases, increased Sertoli cell prolif-
eration was detected by the presence of small hypere-
chogenic foci in ultrasound imaging [72]. The typical
somatic activating mutation in the GNAS1 gene, encod-
ing for the Gsα protein involved in the FSH receptor
transduction pathway, was present only in Sertoli cells,
thus resulting in isolated Sertoli cell hyperfunction with
Sertoli cell hyperplasia and increased AMH (Table 2),
without activating Leydig cells [70].
Sex-cord stromal tumors
AMH immunohistochemistry is useful to identify the sex-
cord stromal origin in testicular tumors. AMH expression
has been shown in overt Sertoli cell tumors [73, 74], in
large cell calcifying Sertoli cell tumors frequently associ-
ated with Peutz-Jeghers syndrome [74], in primary or
metastatic granulosa cell tumors of the testis [73], and in
intratubular Sertoli cell proliferations, which has been sug-
gested to represent an “in situ” or early stage of Sertoli cell
tumors [74]. Although a single determination of serum
AMH may not be helpful to establish the initial diagnosis
of the tumors in most of pediatric cases, because high
AMH is normally found in the prepubertal boy, increasing
AMH levels may be suggestive of a progressive lesion.
Cancer survivors
Chemotherapy and radiotherapy affect primarily germ
cells of the testis, while steroid secreting Leydig cells are
less affected. Sertoli cell function has not been extensively
studied in cancer survivors. Two reports including few pa-
tients treated with poly-chemotherapy or hematopoietic
cell transplantation for medulloblastoma or posterior fossa
ependymoma have shown AMH below normal range for
age [75, 76], whereas our group could not demonstrate
any decrease in serum AMH in a large series of patients
with Acute Lymphoblastic Leukemia or Lymphoblastic
Lymphoma who received poly-chemotherapy [77].
Ambiguous genitalia
When a 46,XY newborn is born with ambiguous or female
genitalia, i.e. a 46,XY disorder of sex development (DSD),
causes of insufficient virilization should be investigated
[78]. 46,XY DSD may result from disorders affecting both
tubular and interstitial testicular compartments, like go-
nadal dysgenesis, or from a condition affecting only the
interstitial compartment, like Leydig cell aplasia or ste-
roidogenic enzyme defects. While testosterone is low in
both situations, serum AMH is helpful to establish a dif-
ferential diagnosis since it is low in patients with gonadal
dysgenesis but normal or high in patients with isolated an-
drogen deficiency [53, 62, 78–80] (Table 2 and Fig. 3).
Alternatively, the action of androgen in target tissue
may be affected in the androgen insensitivity syndrome. In
these patients, both Sertoli and Leydig cell activity is pre-
served, as reflected by normal to elevated serum AMH
and androgen levels [53, 62, 78–80] (Table 2 and Fig. 3).
In boys with isolated hypospadias, AMH and testosterone
are usually normal, indicating that there is no testicular dys-
function, and a malformative DSD should be suspected.
When hypospadias is associated with other clinical manifes-
tations of undervirilization like cryptorchidism, a higher
risk of abnormal hormone secretion by the gonads or an-
drogen end-organ defects exists [81, 82].
The Persistent Müllerian Duct Syndrome is a rare
form of 46,XY DSD usually diagnosed by the unexpected
finding of Müllerian duct remnants during a surgical
procedure for cryptorchidism. Serum AMH levels are
useful to differentiate its etiology, with normal serum
AMH in patients with AMH receptor mutations and ex-
tremely low or undetectable AMH levels in patients with
AMH gene mutations [62] (Table 2).
In 46,XX DSD patients with ambiguous external geni-
talia, AMH levels above the normal female range ex-
clude the diagnosis of congenital adrenal hyperplasia,
aromatase defects or virilizing tumors, and are highly
suggestive of an Ovotesticular DSD [53, 78, 83].















Fig. 4 Serum AMH as a marker of increased intratesticular androgen
activity in patients with precocious puberty. AMH levels at diagnosis,
during and after treatment in six patients with central precocious
puberty. Each color line represents a different patient. Serum AMH is
low for age in four of the boys with precocious puberty, indicating
that there is a high intratesticular testosterone concentration that
inhibits AMH expression. When testosterone production is curtailed
by treatment with a GnRH analogue, serum AMH recovers
prepubertal levels until treatment is withdrawn. In the remaining
two cases (arrows), diagnosed before the age of 1 year, the
explanation for normal prepubertal AMH levels at diagnosis,
indicating a lack of AMH expression in spite of high androgen levels,
is that Sertoli cells do not yet express the androgen receptor at that
age. The shaded areas represent normal reference AMH levels for
age. Reprinted, with modifications, from: Copyright 2013 R.P. Grinspon
et al [18]
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In fully virilized 46,XX DSD patients (XX males),
AMH and testosterone are in the normal male range
(Table 2), indicating that Leydig and Sertoli cells are not
primarily affected [53, 78]. However, germ cells fail to
progress through meiosis and undergo apoptosis at pu-
berty, associated with low testicular volume [84].
Conclusions
Serum AMH is an extremely helpful marker for asses-
sing testicular function in pediatric patients. In 46,XY
patients with non-palpable gonads and in newborns with
DSD, serum AMH is informative about the existence
and functional capacity of testicular tissue. Serum AMH
levels are commensurate with the amount of functional
Sertoli cells present in prepubertal patients, including
those with micro- or macro-orchidism, or ovotesticular
DSD. Serum AMH is also a reliable marker of FSH
action in the prepubertal testis, both in basal conditions
to diagnose central hypogonadism and to monitor FSH
treatment. Finally, declining serum AMH is indicative of
effective androgen action within the seminiferous
tubules, and therefore a useful marker in the diagnosis
and follow-up of patients with precocious or delayed
puberty.
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